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Background: Glucagon-like peptide-1 (GLP-1) and its mimetics reduce infarct size in the setting of acute
myocardial ischemia/reperfusion (I/R) injury. However, the short serum half-life of GLP-1 and its mimetics may limit
their therapeutic use in acute myocardial ischemia. Domain antibodies to serum albumin (AlbudAbs) have been
developed to extend the serum half-life of short lived therapeutic proteins, peptides and small molecules. In this
study, we compared the effect of a long acting GLP-1 agonist, DPP-IV resistant GLP-1 (7–36, A8G) fused to an
AlbudAb (GAlbudAb), with the effect of the GLP-1 mimetic, exendin-4 (short half-life GLP-1 agonist) on infarct size
following acute myocardial I/R injury.
Methods: Male Sprague–Dawley rats (8-week-old) were treated with vehicle, GAlbudAb or exendin-4. Myocardial
ischemia was induced 2 h following the final dose for GAlbudAb and 30 min post the final dose for exendin-4. In a
subgroup of animals, the final dose of exendin-4 was administered (1 μg/kg, SC, bid for 2 days) 6 h prior to
myocardial ischemia when plasma exendin-4 was at its minimum concentration (Cmin). Myocardial infarct size, area
at risk and cardiac function were determined 24 h after myocardial I/R injury.
Results: GAlbudAb and exendin-4 significantly reduced myocardial infarct size by 28% and 23% respectively,
compared to vehicle (both p < 0.01 vs. vehicle) after I/R injury. Moreover, both GAlbudAb and exendin-4 markedly
improved post-ischemic cardiac contractile function. Body weight loss and reduced food intake consistent with the
activation of GLP-1 receptors was observed in all treatment groups. However, exendin-4 failed to reduce infarct size
when administered 6 h prior to myocardial ischemia, suggesting continuous activation of the GLP-1 receptors is
needed for cardioprotection.
Conclusions: Cardioprotection provided by GAlbudAb, a long acting GLP-1 mimetic, following myocardial I/R injury
was comparable in magnitude, but more sustained in duration than that produced by short-acting exendin-4. Very
low plasma concentrations of exendin-4 failed to protect the heart from myocardial I/R injury, suggesting that
sustained GLP-1 receptor activation plays an important role in providing cardioprotection in the setting of acute
myocardial I/R injury. Long-acting GLP-1 agonists such as GAlbudAb may warrant additional evaluation as novel
therapeutic agents to reduce myocardial I/R injury during acute coronary syndrome.
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Glucagon-like peptide-1 (GLP-1) is an incretin hormone
secreted by intestinal L-cells in response to nutrient
ingestion [1]. GLP-1 occurs endogenously in a number
of biologically active isoforms including full length
GLP-1 (7–36) amide, a glycine-extended isoform of GLP-1
(7–37), and the N terminus cleaved GLP-1 (9–36). GLP-1
regulates glucose homeostasis by stimulating insulin
secretion, inhibiting glucagon secretion, delaying gastric
emptying and promoting satiety [2]. Although the major
physiological functions of GLP-1 are associated with
glycemic control, increasing evidence indicates that GLP-1
may also play an important role in cardiovascular physi-
ology [3]. It has been reported that GLP-1 receptors are
expressed in both heart and coronary vasculature [4] and
activation of GLP-1 receptors by agonists results in a
range of cardiovascular effects including cardioprotection
against myocardial ischemic injury both ex vivo [5-7] and
in vivo [8-13].
Active GLP-1 (7–36) has a very short half-life of about
2 min following exogenous administration as it is rapidly
cleaved and inactivated in circulation by the protease
dipeptidyl peptidase-IV (DPP-IV) [14,15]. This short half-
life limits its use as a therapeutic agent as demonstrated
by the fact that clinical studies with exogenous GLP-1
are typically constrained to a continuous infusion dosing
strategy [12,13]. Several GLP-1 receptor agonists, including
exendin-4, have been identified exhibiting an extended
plasma half-life. Exendin-4 is a 39 amino acid peptide
originally derived from the saliva of the gila monster.
It has been shown to have both insulinotropic and
insulinomimetic effects mediated by activation of GLP-1
receptors [16,17]. Exendin-4 also limits myocardial infarct
size both in large animal and human studies [18-20]. Al-
though exedin-4 has a longer plasma half-life than native
GLP-1 (60 min vs. 2 min) [21], it still requires twice daily
injection to achieve anti-diabetic effects. Therefore, several
other approaches have been developed to extend the serum
half-life of GLP-1, such as, a fusion of DPP-IV resistant
GLP-1 dimer with albumin (albiglutide) which has a
long half-life (5 days in human) [22] and provides
cardioprotection in a rat model of myocardial I/R in-
jury [11]. Another approach fuses the GLP-1 “warhead”
to small antibody binding domains (11–13 KDa) that
have high affinity and specificity for human serum
albumin (AlbudAbs) [23-27]. Here, we describe the
creation of GAlbudAb, DOM7h-14 (a domain anti-
body, dAb) genetically fused with GLP-1 (7–36, A8G),
with alanine at position 8 replaced by glycine to render
the peptide DPP-IV resistant, resulting in a agent with
prolonged half-life and pharmacological activity in a rat
model of I/R injury. We also compare its cardioprotective
action to exendin-4. We hypothesized that because of its




GAlbudAb was generated by DNA synthesis. Briefly,
GLP-1 (7–36) peptide with an A8G mutation was put
N terminal of a helical linker [28] that was N terminal
of the DOM7h-14 AlbudAb [25]. This was cloned for
expression into the PTT5 vector system. Expression was
performed in transfected HEK293E cells. Following trans-
fection, cells were cultured in Freestyle media (Invitrogen #
12338-026) supplemented with 25 μg/ml G418 (PAA) and
0.001% (v/v) Pluronic (Invitrogen, #24040-032) at 37°C/5%
CO2 at 125 rpm, and harvested after 120 h. Protein was
purified from clarified supernatant by affinity capture using
protein L coupled to NHS streamline resin (GE Healthcare)
followed by cationic exchange chromatography (SP FF, GE
Healthcare, #17-5157-01). The identity of the final material
was assessed by intact mass analysis. Sample purity was
assessed by reverse-phase HPLC.
In vitro assays of GAlbudAb activity and its affinity
to serum albumin
For analysis of GAlbudAb affinity for serum albumin,
500 resonance units of albumin were coupled to a CM5
Biacore chip and binding curves generated by flowing
protein diluted in Biacore HBS-P + buffer at a range of
concentrations of protein in the range 39 nM to 5 μM
across the Biacore chip. Affinity (KD) was calculated by
fitting on-rate and off-rate curves for traces generated in
the range of the kDa for the dAb. For analysis of GLP-1
activity, GAlbudAb was tested for the ability to induce
cAMP-driven luciferase production in Chinese Hamster
Ovary cells stably transfected with both human GLP-1
receptor and a luciferase reporter gene containing 6 cAMP
response elements within the promoter [29,30]. Data were
normalized to non-treated control cells and analysed using
Prism (GraphPad software) to fit non-linear regression
curves and derive the EC50. The affinity of GAlbudAb for
human, cynomolgous monkey and rat serum albumin was
determined by BIAcore analysis. The fusion protein was
passed over the surface of a CM5 chip coated with serum
albumin and the equilibrium dissociation constant, KD,
determined as a measure of affinity using the 1:1 inter-
action model in BiaEval software.
Pharmacokinetic profile of GAlbudAb and exendin-4
following a single subcutaneous administration and
simulation of multi-dose pharmacokinetics
Male Sprague–Dawley rats (8-week-old) purchased from
Charles-River laboratory (Wilmington, DE) were used for
the study. All animal studies were performed in compliance
with the Guide for the Care and Use of Laboratory Animals
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were approved by the Institutional Animal Care and Use
Committee of GlaxoSmithKline. Rats were administered
GAlbudAb subcutaneously at a dose of 1 mg/kg, and blood
samples were collected at 1, 2, 4, 8, 24, 48 and 72 h post
dose. In exendin-4 PK group, rats were administered
exendin-4 subcutaneously at a dose of 10 μg/kg, and blood
samples were collected at 10 min, 30 min, 60 min, 2, 4 and
8 h post dose. Based on the plasma concentrations of
GAlbudAb at the dose of 1 mg/kg, a pharmacokinetic
model was developed and parameters were estimated using
WinNonlin version 5.1 (Pharsight Corporation). Computer
simulations were also performed using WinNonlin version
5.1 to project the required dose for the in vivo cardio-
protection study. GAlbudAb doses for the rat I/R injury
experiment were selected with the goal that trough
concentrations should be above 1000 ng/ml. A target
of > 1000 ng/ml was based on previous in vitro efficacy
data showing GLP-1 receptor activation. Similarly, PK
modeling analysis for exendin-4 was performed to project
maximum concentration (Cmax) and minimum concentra-
tion (Cmin) following multiple doses of 1 μg/kg subcutane-
ous administration.
Myocardial ischemia/reperfusion injury, LV hemodynamic
measurement and postmortem analysis in
Sprague–Dawley rats
Sprague–Dawley rats were treated with vehicle or with
GAlbudAb at doses of 0.6 mg/kg, 2 mg/kg and 6 mg/kg
once daily by subcutaneous injection for two days or with
exendin-4 (Phoenix Pharmaceuticals, INC) at 0.1 μg/kg,
1 μg/kg and 10 μg/kg, twice daily by subcutaneous injection
for two days. The timing of the final dose was determined
by the PK modeling to obtain Cmax during the early reper-
fusion period. The final dose was administered 2 h prior
to myocardial ischemia for GAlbudAb and 30 min prior
to myocardial ischemia for exendin-4. Then, rats were
subjected to 30 min myocardial ischemia followed by 24 h
reperfusion as previously described [11,31,32]. In order to
determine whether the GLP-1 target needed to be engaged
continuously to provide cardioprotection, myocardial I/R
injury was evaluated 6 h after exendin-4 treatment (1 μg/kg)
using the same dosing regimen as above at the time
when plasma concentrations of exendin-4 was at Cmin. LV
hemodynamic and myocardial infarct size was determined
as previously described [11,24,25]. Briefly, at the end of
study, rats were anesthetized with 2% isoflurane in oxygen
and a 2 F Millar Mikro-tip catheter transducer was
inserted into the left ventricle through the right carotid
artery to measure left ventricular pressure and both
systolic and diastolic left ventricular function (dP/dtmax and
dP/dtmin, respectively). After hemodynamic measurements,
the heart was excised and perfused with saline to wash out
residual blood through an aortic cannula. To delineateinfarcted tissues from viable myocardium, the heart was
then perfused with a 1% solution of 2,3,5-triphenyltetrazo-
lium chloride (TTC) in phosphate buffer (pH 7.4, 37°C).
The viable myocardium was stained red, and the infarcted
myocardium was stained white. To delineate the area at
risk (ischemic area), the coronary artery was then tied at
the site of the previous occlusion and the aortic root
was perfused with a 1% Evans blue dye (Sigma) in normal
saline. As a result of this procedure, the portion of the LV
supplied by the previously occluded coronary artery (area
at risk) was identified by the absence of blue dye, whereas
the rest of the LV was stained dark blue. The heart was
frozen, after which all atrial and right ventricular tissues
were excised. The LV was cut into 4–5 transverse slices,
which were photographed using a digital camera. The
borders of the infarct, area at risk and area of non at risk of
heart images were traced and measured using Image-Pro
Plus. Area at risk and infarct size was calculated using
the following mathematical formulas: Area at risk = sum
of area at risk/(sum of area at risk + sum of area not at
risk) × 100%; infarct size = (sum of infarct area/sum of
area at risk) × 100%.
Biochemical analysis, clinical chemistry, exendin-4
and GAlbudAb bioanalysis
Plasma insulin was measured using an MDS rat insulin Kit
(K152BZC-2). Plasma glucose and lactate were measured
in non-fasted animals using an Olympus AU 640 analyzer
(Olympus America Inc., Melville, NY). Plasma levels of
exendin-4 were measured using an exendin-4 ELISA kit
(Bachem, San Carlos, CA). Plasma GAlbudAb concentra-
tions were quantified using an analytical method based on
sample dilution followed by LC-MS/MS analysis. Briefly,
working solutions were prepared from the GAlbudAb
stock solution at 1, 10 and 100 μg/mL in rat plasma. From
these working solutions, a standard curve was prepared
with nominal concentration of 100, 250, 500, 1000, 2500,
5000 and 10000 ng/mL in rat plasma. Then, samples,
standards, QC samples and blanks were aliquoted (50 μL)
into separate 1.4 mL polypropylene tubes. This was
followed by digestion using 75 μL of Lys-C solution
(1 IU of Lys-C/mL of 100 mM sodium bicarbonate buffer
pH 8.5) and incubated overnight at 37°C with constant
shaking. To stop the digestion samples were acidified with
formic acid and subjected to solid phase extraction using
Strata XC strong cation exchange resin (Phenomenex)
according to the manufacturer’s peptide extraction proced-
ure. The resultant peptides were resuspended in 90/10/0.1
water/acetonitrile/formic acid for LC-MS/MS analysis.
Peptides were separated on an Acquity BEH-C18 1.7 μm
2.1 × 50 mm column with a column temperature held at
65°C and a flow rate of 0.7 mL/min. HPLC-MS/MS
analyses were performed on a triple quadrupole mass
spectrometer API5000 (Applied Biosystems/MDS Sciex)
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equipped with a Waters Acquity UPLC system. MS data
was acquired and processed using the proprietary software
application Analyst version 1.4.2 (Applied Biosystems/MDS
Sciex). Calibration plots for the LC-MS/MS assay of ana-
lyte/IS peak area ratio were plotted versus concentration
and a weighted 1/x2 linear regression was applied to the
data.
Statistical analysis
Data are presented as mean ± SEM. Differences between
groups were compared by paired and unpaired Student’s t
tests or by a one-way ANOVA followed by a Bonferroni
test for multiple comparisons. A p value of < 0.05 was
considered statistically significant.
Results
Characterization, expression and in vitro activity
of GAlbudAb
GAlbudAb fusion protein was cloned into a pTT5-based



































Figure 1 Amino acid sequence of GAlbudAb and activity of GAlbudA
the human DPK9 - Jk1 germline gene, the GLP-1 (7–36) peptide and exend
determined by the method of Kabat (A). Activity of native GLP-1 (7–36) anand purified directly from tissue culture supernatant
following 5 days culture. Alanine at position 8 of GLP-1
(7–36) was replaced with glycine to render it DPP-IV
resistant. The amino acid sequences of the fusion protein
and its alignment to GLP-1 (7–36) peptide, exendin-4 and
the germ-line DPκ9-JK1 sequence are shown in Figure 1A.
Purified protein produced a single band of expected mass
on SDS-PAGE as well as the expected mass by mass
spectrometry (data not shown).
To determine whether the purified fusion protein was
active, GLP-1 activity was assayed using a GLP-1 receptor
CHO reporter assay (Figure 1B) in which CHO cells
are stably transfected with a GLP-1 receptor gene and
a luciferse reporter gene under the control of a 6 cAMP
response element promoter. Treatment of this cell line
with GLP-1 receptor agonists results in induction of
reporter gene expression in a manner dependent upon the
level of GLP-1 receptor activation. The GLP-1(7–36) pep-
tide and the fusion protein induced reporter gene expres-
sion in this cell line with equivalent potency (EC50 = 100
pM). Affinity of the fusion protein for human, cynomolgus-11 -10 -9 -8
ation (Log M)
b. The sequence was aligned with that of the amino acid sequence for
in-4 using the Clustal V algorithm. Residue numbering was
d GAlbudAb in CHO reporter assay (B).
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275 nM, respectively.
Pharmacokinetics of GAlbudAb following a single
subcutaneous injection in Sprague–Dawley rat
Rat plasma concentrations of GAlbudAb and exendin-4
(Figure 2A) following a single subcutaneous injection
(1 mg/kg and 10 μg/kg, respectively) were determined
using LC-MS/MS analysis and ELISA assay. The time
to peak concentration for GAlbudAb was 8 h and the
maximum plasma concentration for GAlbudAb was
523 ± 98 ng/ml as determined by LC-MS/MS. GAlbudAb
was detected in circulation for at least 24 h. The time
to peak concentration for exendin-4 was 1 h and the
maximum plasma concentration for exendin-4 was


















































































Figure 2 Rat GAlbudAb and exendin-4 pharmacokinetic
analysis and computer simulation for predicting plasma drug
concentrations. A, Plasma GAlbudAb concentrations following
1 mg/kg subcutaneous administration and blood samples were
collected at 1, 2, 4, 8 and 24 h and plasma exendin-4 concentrations
following 10 μg/kg subcutaneous administration and blood samples
were collected at 10 min, 30 min, 60 min, 2, 4 and 8 h (n = 3/group).
B, Computer simulated GAlbudAb concentration curves at a
projected dose of 2 mg/kg, which achieved a sustained exposure
above 1000 ng/ml after 48 h and computer simulated exendin-4
concentration curves following 1 μg/kg twice daily SC dosing of
exendin-4 for 3 days, which showed exendin-4 was at its Cmin 6 h
post dose.Based on this initial pharmacokinetic profiling, a com-
puter simulated analysis was performed to project plasma
concentrations of GAlbudAb and exendin-4 following
multiple days dosing and to determine the dose required
for the in vivo cardioprotection study. As shown in
Figure 2B, simulated plasma concentrations of GAlbudAb
following a subcutaneous injection at a dose of 2 mg/kg/
day for 3 days were above 1000 ng/ml, the target plasma
concentration for the in vivo study. In contrast to
GAlbudAb, simulated plasma concentrations revealed
that exentin-4 was at its Cmin 6 h post the final dose
(Figure 2B). Final dose selection for GAlbudAb bracketed
this target level and contained a one-log concentration
range. Dose selection for exendin-4 was based on previous
studies [18,33].
Myocardial infarct size and area at risk following
ischemia/reperfusion injury
A total of 72 rats were subjected to 30 min ischemia and
24 h reperfusion and 70 rats survived the procedure. One
rat from the vehicle group died at 2 h post reperfusion
and one rat from the GAlbudAb low dose group (0.6 mg/
kg/day) died overnight after reperfusion. Representative
transverse sections of the heart stained by TTC and Evans
blue from each group are shown in Figure 3A. Myocardial
infarct size averaged 56.8 ± 2.0% of area at risk in the
vehicle group after myocardial I/R injury while treatment
with exendin-4 at the doses of 0.1, 1 or 10 μg/kg reduced
infarct size to 55.1 ± 2.1%, 44.0 ± 3.7% and 43.5 ± 3.7% of
area at risk (reduced by 2.9%, 22.5% and 23.3% vs. vehicle,
respectively) (Figure 3C). Infarct size was 52.5 ± 2.5%
of area at risk (i.e. comparable to infarct size following
vehicle treatment) in the exendin-4 group treated 6 h
prior to myocardial ischemia at the Cmin (Figure 3C).
Area at risk was comparable across all groups (Figure 3B).
Treatment with GAlbudAb significantly reduced infarct
size. Infarct size was 49.1 ± 2.8%, 43.7 ± 3.0%, and 46.5 ±
3.1% of area at risk at doses of 0.6, 2 or 6 mg/kg (reduced
by 19%, 28% and 24% vs. vehicle, respectively, all p < 0.05)
(Figure 4A and C). Area at risk was comparable between
vehicle- and GAlbudAb-treated groups (Figure 4B).
Cardiac function following ischemia/reperfusion injury
There was no difference in heart rate or LV systolic
pressure between vehicle- and GAlbudAb-treated animals
(Table 1). However, the increased LV end diastolic pressure
induced by myocardial I/R injury was markedly attenuated
by GAlbudAb (8.6 ± 1.5 mmHg vs. 12.8 ± 1.0 mmHg in
vehicle, p < 0.05) (Table 1). Additionally, the impaired
contractile and relaxation function post-myocardial I/R in-
jury were significantly improved with GAlbudAb treatment
by 14.8% and 18.7% respectively, compared to vehicle
(7612 ± 219 mmHg/s vs. 6628 ± 273 mmHg/s for dP/














































































































Figure 3 Effect of exendin-4 on infarct size and area at risk following acute myocardial ischemia/reperfusion injury. Sprague–Dawley
rats were subjected to 30 min LAD coronary artery occlusion followed by 24 h reperfusion. Hearts were harvested and analyzed for area at risk
and infarct size. Representative photographs of heart sections from vehicle, 0.1, 1, 10 μg/kg and 1 μg/kg exendin-4 at Cmin (from left to right)
stained by 2,3,5-triphenyltetrazolium chloride (TTC) and Evans blue dye illustrate myocardial infarct (white), area at risk (white and red) and area
not at risk (dark blue) (A). Myocardial infarct size was assessed as percentage of area at risk in the left ventricle (B). The area at risk was assessed
as percentage of the left ventricle area (C). Values are presented as mean ± SEM. *p < 0.05 and **p < 0.01 vs. vehicle (n = 8-10/group).
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ischemic cardiac function (data not shown).
Body weight, food consumption, and plasma levels of
insulin, glucose, lactate and GAlbudAb concentrations
pre-ischemia and 24 hrs post-reperfusion
GAlbudAb significantly reduced body weight and food
consumption in a dose-dependent manner following
two days of dosing, which is consistent with the known
pharmacology of GLP-1 mimetics (Figure 5A and B).GAlbudAb also decreased pre-ischemia plasma glucose
compared to vehicle at all doses (Figure 6A). There was
no difference in plasma lactate between GAlbudAb and
vehicle-treated rats (Figure 6B). Plasma concentrations of
GAlbudAb prior to a 30 min myocardial ischemia were
2476 ± 561 ng/ml and 2606 ± 175 ng/ml at the doses of
2 mg/kg and 6 mg/kg, respectively, which were above the
projected drug exposure to activate GLP-1 receptors when
myocardial I/R injury occurred. The terminal plasma



























































































Figure 4 Effect of AlbudAb on infarct size and area at risk following acute myocardial ischemia/reperfusion injury. Sprague–Dawley rats
were subjected to 30 min LAD coronary artery occlusion followed by 24 h reperfusion. Hearts were harvested and analyzed for area at risk and
infarct size. Representative photographs of heart sections from vehicle, and 0.6, 2, or 6 mg/kg GAlbudAb treated group (from left to right) stained
by 2,3,5-triphenyltetrazolium chloride (TTC) and Evans blue dye illustrate myocardial infarct (white), area at risk (white and red) and area not at risk
(dark blue) (A). Myocardial infarct size was assessed as percentage of area at risk in the left ventricle (B). The area at risk was assessed as
percentage of the left ventricle area (C). Values are presented as mean ± SEM. *p < 0.05 and ***p < 0.001 vs. vehicle (n = 4-9/group).
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2 mg/kg and 6 mg/kg, respectively.
Discussion
In this study, we demonstrate that fusion of a domain
antibody with high affinity and specificity for human
serum albumin (AlbudAb) to a DPP-IV resistant GLP-1
(7–36, A8G) peptide produced a potent GLP-1 agonist
with an extended plasma half-life and cardioprotective
activity in an acute model of myocardial I/R injury. The
cardioprotective effects of GAlbudAb were further con-
firmed by improvement in post-ischemic cardiac function.The cardioprotective effects of GAlbudAb were equieffi-
cacious when compared to exendin-4 and were consistent
with the known effects of GLP-1 receptor activation, i.e.
dose-dependent reduction in body weight, food intake and
plasma glucose. However, GAlbudAb provided an infarct-
limiting effect following myocardial I/R injury that was of
similar magnitude, but longer duration than that produced
by exendin-4, which failed to protect the heart against I/R
injury at 6 h post dosing when plasma exendin-4 concen-
trations were projected to be very low and considerably
below concentrations previously shown to be necessary
















































































Figure 6 Blood glucose (A) and blood lactate (B) after 2 days
GAlbudAb treatment. Values are presented as mean ± SEM.
*p < 0.05 vs. vehicle.
Table 1 Effect of GAlbudAb on post-ischemic left
ventricle hemodynamic
Parameter Vehicle GAlbudAb (2 mg/kg)
N 8 9
LVSP (mmHg) 107 ± 3.0 112 ± 2.6
LVEDP (mmHg) 12.8 ± 1.0 8.6 ± 1.5*
HR (bpm) 425 ± 5 419 ± 10
dP/dtmax (mmHg/s) 6628 ± 273 7612 ± 219*
dP/dtmin (mmHg/s) 5682 ± 311 6746 ± 341*
N, number of animals; LVSP, left ventricle systolic pressure; LVEDP, left
ventricle end diastolic pressure; HR, heart rate; dP/dtmax, maximum rates of
change in the left ventricle pressure; dP/dtmin, minimum rates of change in left
ventricle pressure. Data are presented as mean ± SEM. *p < 0.05 vs. vehicle.
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by GAlbudAb were verified in this study; GAlbudAb
dose-dependently reduced animal body weight gain, which
was associated with a reduction in rat food intake. A
glucose lowering effect of GAlbudAb was also observed
in the present study. The observed pharmacological effects
of GAbuldAb are consistent with the stability of this
construct in vitro and in vivo (Figure 1B and Figure 2A).
These findings suggest that in addition to providing
peripheral glycemic control, GAlbudAb may have direct
therapeutic potential for limiting myocardial infarct size
and improving cardiac function in the setting of acute
myocardial ischemic injury.
GLP-1 and its various mimetics have been shown to be
cardioprotective in the setting of myocardial I/R injury
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Figure 5 Body weight gain (A) and food consumption (B) after
2 days GAlbudAb treatment. Values are presented as mean ± SEM.
**p < 0.01 and ****p < 0.0001 vs. vehicle.version of exendin-4, reduced myocardial infarct size
by 40% in a porcine model of myocardial I/R injury [18].
More recently, Lonborg et al. demonstrated that exenatide
reduces final infarct size in patients with ST-segment-
elevated myocardial infarction and a short-duration of
ischemia [20]. In line with these previous findings, we
confirmed the infarct-size limiting effects of exendin-4 in
our rat model of myocardial I/R injury. We also explored
the cardioprotective effects of exendin-4 following twice
daily subcutaneous administration when plasma drug con-
centrations were very low. Exendin-4 failed to demonstrate
an infarct size limiting effect when plasma exendin-4 at its
Cmin, indicating that a certain level of plasma exposure of
exendin-4 is critical to protect the heart from myocardial
I/R injury and to activate the cardiac GLP-1 receptor. In
contrast to exendin-4, GAlbudAb has a longer serum half-
life. Plasma concentrations of GAlbudAb during 30 min
ischemia and early reperfusion period (2476 ± 561 ng/ml)
were above the required threshold exposure to activate
GLP-1 receptors (1000 ng/ml), and a substantial concen-
tration of GAlbudAb in circulation was detected even
26 h post final dose (1667 ± 611 ng/ml). Therefore, it can
be postulated that GAlbudAb would result in increased
duration of cardioprotection versus exendin-4 in our
rat model of myocardial I/R injury. However, maximal
cardioprotection between GAlbudAb and exendin-4 was
similar (28% vs. 23% of myocardial infarct reduction, re-
spectively). These findings are further supported by clinical
data in diabetic patients in which sustained pharmacology
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control [34,35].
Several mechanisms by which GLP-1 and its mimetics
render cardioprotection have been previously identified
[18,36-41]. Timmers et al. have shown that exenatide
reduces myocardial infarct size, decreases oxidative
stress and inhibits caspase-3 expression and DNA frag-
mentation in a porcine model of myocardial I/R injury
[18]. Ye et al. have demonstrated that increases in cAMP,
PKA and activation of Akt by exendin-4 contribute to the
cardioprotection by exendin-4, which results in enhanced
post-ischemia cardiac function [38]. More recently, we
demonstrated that increases in glucose metabolism and
a shift toward a more energetically favorable substrate
metabolism by increasing both glucose and lactate oxida-
tion also play an important role in GLP-1 analog mediated
cardioprotection in the rat [11]. Furthermore, Ku et al.
reported DPP4 deficient rats exhibited improved cardiac
function following myocardial I/R injury via activation
of GLP-1 receptor and its downstream signaling [39].
Myocardial I/R injury initiates an inflammatory cascade
and a recent study revealed that cytoprotection against
hypoxia produced by exendin-4 in human islets was
associated with inhibition of inflammatory genes through
activation of cAMP response element binding protein
[41]. However, it appears cardioprotection produced by
GAlbudAb is in large part due to direct cardiomyocyte
protection because GAlbudAb not only reduced myocardial
infarct size but also significantly enhanced post-ischemia
LV function. Xiao et al. demonstrated that GLP-1 increased
cardiomyocyte contractility through enhancing cardiac
L-type Ca2+ current via activation of the cAMP-deperndent
protein kinase A pathway [40]. It is possible that these
mechanisms are also involved in the cardioprotection
mediated by GAlbudAb, but the precise mechanism by
which cardioprotection is rendered by GAlbudAb war-
rants future research. Previous studies also suggest that
cardioprotection might be elicited by GLP-1 (9–36) via
GLP-1 receptor independent pathways [10]. However,
GLP-1 (9–36) AlbudAb (data not shown), didn’t signifi-
cantly reduce myocardial infarct size in this study and it
also had no effect on body weight and food intake following
two days of treatment, suggesting activation of the GLP-1
receptor dependent pathway by GAlbudAb plays an
important role in cardioprotection. In addition, the GLP-1
(7–36, A8G) engineering rendered the peptide DPP-IV
resistant thereby limiting the amount of GLP-1 (9–36)
generated in vivo. These results were consistent with
GLP-1 receptor activation. Although GLP-1 receptors have
been identified in cardiomyocytes and endothelial cells, an
indirect benefit to the heart via systemic glucose/insulin
regulation cannot be ruled out.
In this study, we demonstrate that GAlbudAb produced
both glucose-lowering and cardioprotective effects, suggestingthat GAlbudAb may have potential both to manage
hyperglycemia and to limit myocardial ischemia injury
in patients with diabetes mellitus who are at high risk for
coronary artery disease and acute coronary syndrome.
Moreover, the results demonstrate that extended plasma
exposure and resulting extended period of GLP-1 receptor
activation produced by GAlbudAb prolonged the period
of ischemic protection. Additional studies would be
required to determine whether this observation would
be translated into a greater period of protection from
ischemic injury in patients with diabetes mellitus and
coronary artery disease.
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